Bausch Health Companies | Investor Conference Presentation Deck

Slide schematic 6/6

disclaimer 1/1 list 2/2 title 3/3

Components 6

disclaimer bullet bullet headline headline subtitle

Tools 1

list/bullet: Amiselimod is a new oral selective S1P2 receptor modulator; shows potent selectivity for S1P1; clean cardiac profile; differentiated from ozanimod (no titration, greater lymphocyte reduction, mild/moderate i

Metrics 0

∅

No metrics

No metric insight is anchored to this slide.

Frameworks 0

∅

No frameworks

No framework match is anchored to this slide.

Find anything

Includes footnote references for licensing and S1P definition.